Despite advancements in lupus management over the past two decades, infection remains a significant cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). 1 2 Various ...

Systemic lupus erythematosus (SLE) is a clinically and immunologically heterogeneous autoimmune disease that can be challenging to diagnose, especially in its early stages. Although developed in the ...

Clinicians remain believers in B-cell depletion despite the failure of rituximab in the EXPLORER, LUNAR, and BELONG clinical trials. 1–3 Additional studies suggested that the B-cell depletion that ...

The British Isles Lupus Assessment Group (BILAG)-2004 index is a comprehensive disease activity instrument for systemic lupus erythematosus (SLE). 1 Its key advantages are the ability to capture rare ...

Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids.2 As ...

A key lupus outcome measure is the assessment of damage, which is considered as a separate domain to disease activity and health related quality of life and has been shown to independently predict ...

Background/ Purpose We recently showed that in SLE, IL-4 suppressed the development of interferon-beta (IFNβ) and TLR7-stimulated T-bet + double negative 2 (DN2) B cells. Here we investigate the ...

Background Persistent production of type I interferons (IFN-Is) is one of the hallmarks of lupus skin disease that is exacerbated by ultraviolet (UV) light. We previously showed IFN-I induction by UV ...

Conclusions We report substantial differences in lupus nephritis mortality rates by sex, age, geographic region, urbanization level, and race/ethnicity. This study suggests strong, independent and ...

Background Lupus is a complex autoimmune disease characterized by loss of self-tolerance, leading to dysregulated functions of T and B cells. Broadly increased glucose metabolism has been reported in ...

Disclosures AME, JLR, MEBC: Exagen, ImmunovantFunding Duke CTSA grant ( UL1TR002553 )Background The Type 1 & 2 SLE Model encompass symptoms classically attributed to inflammation, including arthritis, ...

Conclusions Voclosporin was well-tolerated over three years of treatment. The significant reductions in proteinuria initially achieved in AURORA 1 were maintained throughout AURORA 2 and more patients ...